| Company Name: |
Shanghai Fuhe Chemistry Technology Co., Ltd.
|
| Tel: |
0086-21-67651709 |
| Email: |
cfx759@hotmail.com |
| Products Intro: |
Product Name:L-Lysine, coMpd. with 4-[2-[(1R,2R)-2-(2,4-difluorophenyl)-1-Methyl-2-[(phosphonooxy)Methoxy]-3-(1H-1,2,4-triazol-1-yl)propyl]-4-thiazolyl]benzonitrile and ethanol (1:1:1) (9CI)
CAS:914361-45-8
|
| Company Name: |
Shanghai Lollane Biological Technology Co.,Ltd.
|
| Tel: |
021-52996696，15000506266 15000506266 |
| Email: |
|
| Products Intro: |
Product Name:Fosravuconazole L-lysine ethanolate
CAS:914361-45-8
Purity:98% HPLC Package:5mg，10mg，50mg，100mg，1g，5g
|
|
| | Fosravuconazole L-lysine ethanolate Basic information |
| Product Name: | Fosravuconazole L-lysine ethanolate | | Synonyms: | L-Lysine, coMpd. with 4-[2-[(1R,2R)-2-(2,4-difluorophenyl)-1-Methyl-2-[(phosphonooxy)Methoxy]-3-(1H-1,2,4-triazol-1-yl)propyl]-4-thiazolyl]benzonitrile and ethanol (1:1:1) (9CI);Fosravuconazole L-lysine ethanolate;BMS-379224 L-lysine ethanolate;E-1224 L-lysine ethanolate;Fungal,onychomycosis,Fosravuconazole Llysine ethanolate,Parasite,parasitemia,inhibit,Fosravuconazole L lysine ethanolate,antifungal,Ravuconazole,Inhibitor,candidiasis,Fosravuconazole L-lysine;(S)-2,6-Diaminohexanoic acid (((2R,3R)-3-(4-(4-cyanophenyl)thiazol-2-yl)-2-(2,4-difluorophenyl)-1-(1H-1,2,4-triazol-1-yl)butan-2-yl)oxy)methyl dihydrogen phosphate and ethanol salt | | CAS: | 914361-45-8 | | MF: | C31H40F2N7O8PS | | MW: | 739.73 | | EINECS: | | | Product Categories: | API | | Mol File: | 914361-45-8.mol |  |
| | Fosravuconazole L-lysine ethanolate Chemical Properties |
| storage temp. | Store at -20°C | | solubility | DMSO : 50 mg/mL (67.59 mM; Need ultrasonic)| (insoluble) | | Water Solubility | Water : < 0.1 mg/mL (ultrasonic) |
| | Fosravuconazole L-lysine ethanolate Usage And Synthesis |
| Biological Activity | Fosravuconazole L-lysine ethanolate (BMS-379224 L-lysine ethanolate), a prodrug of Ravuconazole, is an orally active broad-spectrum antifungal agent. Fosravuconazole L-lysine ethanolate can be used in the study of candidiasis, onychomycosis and parasitic diseases. | | in vitro | Fosravuconazole has potent in vitro antifungal activity against a wide range of fungal species, including Candida , Aspergillus , and Trichophyton species . | | in vivo | Fosravuconazole (E-1224; 10-50 mg/kg; oral administration; daily; for 20 days) treatment suppresses the parasitemia and prevents death in mice infected with the T. cruzi Y strain. | Animal Model: | Swiss female mice (20-24 g) inoculated with trypomastigotes (Y strain). | | Dosage: | 10 mg/kg, 20 mg/kg, 30 mg/kg, 40 mg/kg , 50 mg/kg | | Administration: | Oral administration; daily; for 20 days | | Result: | Suppressed the parasitemia and prevented death. | |
| | Fosravuconazole L-lysine ethanolate Preparation Products And Raw materials |
|